Anti-MiHA donor T-lymphocytes (Institute for Research in Immunology and Cancer)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-MiHA donor T-lymphocytes (Institute for Research in Immunology and Cancer)
Drug Alias Nameimmunodominant minor histocompatibility antigens (cancer)anti-minor histocompatibility complex donor T-lymphocytes (cancer)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunostimulantsT lymphocytes stimulants
TargetsNot applicable
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesInstitute For Research In Immunology And CancerSpecificitHopital Maisonneuve-Rosemont +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesInstitute For Research In Immunology And CancerHopital Maisonneuve-RosemontUniversity Of Montreal +[4] 
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A